Key result
Valsartan and spironolactone therapy is linked to reduced fibrosis markers in elderly hypertensive patients.
Why the study?
Chronic hypertension leads to metabolic disorders in the interstitial matrix of the heart and blood-vessel walls, but involutive and hypertensive changes and their potential correction with valsartan and Veroshpiron required assessment.
Does antihypertensive therapy with valsartan and spironolactone reduce myocardial fibrosis markers in elderly women with stage-II arterial hypertension?
Observational (n=60)
Does antihypertensive therapy with valsartan and spironolactone reduce myocardial fibrosis markers in elderly women with stage-II arterial hypertension?
Antihypertensive therapy with valsartan and spironolactone reduces markers of myocardial fibrosis in elderly women with stage-II arterial hypertension.
The chronic extension of heart and blood-vessel walls due to hypertension leads to metabolic disorders in their interstitial matrix. To assess involutive and hypertensive changes in the cardiac and vascular interstitial matrix and to assess the their potential correction with Valsartan and Veroshpiron, 30 normotensive elderly women and 30 patients of the same age with stage-II arterial hypertension (AH) have been examined. Echocardiography and Doppler cardiography were carried out, the volume fraction of interstitial collagen (VFIC) in the myocardium and cardiovascular conjugation (CVC) was measured, and the serum concentrations of systemic collagenogenesis markers were determined. In elderly patients with AH, a higher intensity of LV myocardial fibrosis was found with a statistically significant increase in VFIC as compared to the patients with normal tension. This was due to the increased activity of fibrosis markers. A decrease in their levels was observed after antihypertensive therapy, which proved the antifibrotic effect of the therapy.
No takes yet. Share an insight, caveat, or question.
Горшунова et al. (2020) conducted an observational in Arterial hypertension (n=60). Valsartan and Veroshpiron vs. Normotensive controls / Baseline was evaluated on Volume fraction of interstitial collagen (VFIC) and serum concentrations of systemic collagenogenesis markers. Antihypertensive therapy with Valsartan and Veroshpiron decreased the levels of fibrosis markers in elderly patients with stage-II arterial hypertension, demonstrating an antifibrotic effect.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: